The London- listed drug company Shire has made a $30 bn hostile takeover bid for the rare-disease specialist Baxalta. Shire announced it was ready to pay $45.23 per Baxalta share, a 36% premium on Baxalta s stock price on Monday. Shire s play for Baxalta comes after it was nearly taken over itself by Illinois- based rival AbbVie in 2014. The
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today reported financial results for the second quarter of 2015 and associated company developments. "Strong growth in product prescriptions in the quarter reflects the solid.
Some of the factors that could cause actual results to differ include: our ability to continue to monetize the licensing of our technology and products; our ability to raise capital; our ability to achieve profitability; our ability to manage our growth effectively; our ability to obtain FDA clearance for our Modified Risk Cigarettes; our ability t
Phase II study to evaluate the efficacy and safety of ALX-0061, administered subcutaneously, in patients with moderate to severe, active systemic lupus erythematosus GHENT, Belgium, 4 August 2015- Ablynx today announced that it has administered the first dose in the Phase II STEADY study to evaluate the efficacy and safety of its anti-IL-6R Nanobod
Aug. 04 Access Carroll recently received a $25,000 from the Quality Health Foundation to support a pharmacy program, regarded in the health care field as pioneering, that helps ensure clients are able to secure the medications they need free of charge through pharmaceutical company financial assistance programs. It's the latest in series of such
Examples of these statements include, but are not limited to, statements regarding: the process and timing of anticipated future development of AcelRx's product candidates, including Zalviso and ARX-04, including the upcoming General Advice meeting with the U.S. Food and Drug Administration, or FDA, for Zalviso scheduled in early September 2015; Ac
-Achillion Pharmaceuticals, Inc. announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 in healthy volunteers. As previously announced on May 19, 2015, Achillion has granted Janssen a
Akorn, Inc. today announced the appointment of Randall Pollard as Chief Accounting Officer and Interim Chief Financial Officer. Mr. Pollard joined Akorn as Vice President and Corporate Controller in April 2015 from Novartis Pharmaceuticals, where he served as the head of accounting and reporting for Novartis' generic division, Sandoz.
Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on developing and commercializing innovative, non-systemic, oral protein therapeutics to treat metabolic and orphan diseases, today announced that the first patient has been treated in its Phase 2 b dose-ranging study of ALLN-177, an orally administered recombinant...
Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its second quarter of 2015 ended June 30, 2015, after the market closes on Wednesday, August 12, 2015, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. This press release contains forward-looking statements, including sta
Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on August 07, 2015. SAN DIEGO& RICHMOND, Va.& LJUBLJANA, Slovenia& SYDNEY AmpliPhi BioSciences Corporation, a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that its board of directors has approved a..
Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many important factors, including those set forth under "Risk Factors" in our annual report on Form 10- K for the year ended December 31, 2014. EXECUTIVE OVERVIEW ANI Pharmaceuticals, Inc. and its wholly-owned, consolidated subsidiary,
Ascendis Health has made its first international acquisition with the purchase of a 49% stake in Spanish pharmaceutical group, Farmalider for R210 million... The Madrid- based company develops and manufactures mainly generic pharmaceutical products, with a market leading position in the ibuprofen and paracetamol markets in Spain. CEO, Dr Karsten We
Release date- 03082015- BRIDGEWATER, NJ- Bausch+ Lomb, a leading global eye health company, announced today its VICTUS Femtosecond Laser Platform has received 510 clearance from the U.S. Food and Drug Administration for an enhanced patient interface kit. The interface features a smaller diameter suction clip, which has been modified to allow for ea
Focus on 4 Emerging Biotech Companies. NEW YORK, NY/ ACCESSWIRE/ August 4, 2015/ Recently, the four tickers Immunomedics Inc., KaloBios Pharmaceuticals Inc., Pluristem Therapeutics Inc., and Arrowhead Research Corp have been attracting investors' attention. Nonetheless, recent years have seen some positive news in relation to FDA approvals and U.S.
Capricor Therapeutics, Inc., a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced the appointment of Deborah D. Ascheim, M.D., to the position of Chief Medical Officer. Prior to her tenure at Mount Sinai, Dr. Ascheim was on faculty in the Department of Medicine and div
Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that Catabasis will present a company overview at the Wedbush PacGrow Healthcare Conference. The Wedbush PacGrow Healthcare Conference will be held August 11- 12, 2015, in New York, NY at Le Parker Meridien
Catalyst Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it will release Second Quarter financial results after market close on Monday, August 10, 2015. Catalyst management will host an investment-community conference call.
Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that it will host a conference call and live audio webcast on Tuesday, August 11, 2015 at 4:30 p.m. ET to report second quarter 2015 financial results.
Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the Wedbush PacGrow 2015 Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is sche
ACI Association has initiated research coverage on Juniper Pharmaceuticals, Inc.. Appointment of New Chairman- On July 16, 2015, Juniper Pharmaceuticals, Inc. announced several changes to its Board of Directors. The specialty pharmaceutical company focused on developing women-related therapeutics informed that James A. Geraghty has been appointed a
Ciclofilin Pharmaceuticals Inc., a privately held biotech, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 13/ 994,707 entitled, "Cyclosporine Analogue Molecules Modified at Amino Acid 1 and 3." This Intellectual Property expands the Company's portfolio of...
-Codexis, Inc., a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces the signing of a CodeEvolver platform technology license agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. This transaction marks the second CodeEvolver licensing agreement between Codexi
As of June 30, 2015 the Company had approximately $93 million in total assets including $53 million in cash and investments. Cumberland also had nearly $44 million in tax net operating loss carryforwards, resulting from the prior exercise of stock options. Progressing with the Caldolor supplemental New Drug Application requesting a label update
"The second quarter of 2015 has been very productive for CytRx. Enrollment in our ongoing pivotal global Phase 3 clinical trial of aldoxorubicin in soft tissue sarcoma continues on track to be completed in the first quarter of 2016. On the financial front, we successfully closed a public equity offering raising an additional $28.8 million in gross